CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia

PHASE1UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 25, 2019

Primary Completion Date

June 1, 2021

Study Completion Date

June 1, 2021

Conditions
T-lymphoblastic LymphomaNK/T Cell LymphomaAcute Lymphocytic Leukemia
Interventions
DRUG

CD7 CAR-T cells infusion

"Biological: CD7 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD7 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD7 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD7 CAR-T cells are infused into patients for one or two times, the number of infused CD7 CAR-T cells are 0.5-5×10\^6/kg."

Trial Locations (1)

450000

RECRUITING

First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

lead

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY